← All trials
NCT06648824
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2024
- Primary completion
- Nov 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Oct 18, 2024
- Last posted
- Oct 18, 2024
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Agios Pharmaceuticals, Inc.Lead sponsor
- Agios Pharmaceuticals, Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.